{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Yojana Gadiya",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "IMGTHLA": "^[A-Z0-9*:]+$",
      "NCIT": "^C\\d+$",
      "ORPHANET": "^\\d+$",
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "EFO": "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "ms/cappa2017.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Lifestyle and environmental factors are established contributors to risk for MS.",
      "key": "1a154c96dcadab5821f094bdaef18321",
      "line": 80,
      "relation": "association",
      "source": 76,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Lifestyle and environmental factors are established contributors to risk for MS.",
      "key": "78dc749e728fdf873a12a1d790ff2316",
      "line": 80,
      "relation": "association",
      "source": 60,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Lifestyle and environmental factors are established contributors to risk for MS.",
      "key": "75a572d615f91ae404069dc4a03ac367",
      "line": 81,
      "relation": "association",
      "source": 60,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "There is a positive association between latitude and prevalence of MS at a global level, unexplained by the genetic distribution of high-risk alleles (12).",
      "key": "c464747b83d4b36ef0d038b16bc293c2",
      "line": 87,
      "relation": "positiveCorrelation",
      "source": 60,
      "target": 87
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Early work has shown that duration of exposure to sunlight and sunlight intensity are associated with MS risk",
      "key": "4d38dcd065575291228800dd91a6fd22",
      "line": 92,
      "relation": "association",
      "source": 60,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Early work has shown that duration of exposure to sunlight and sunlight intensity are associated with MS risk",
      "key": "f5991cb6e3d7df9a688f6a22597e7f03",
      "line": 93,
      "relation": "association",
      "source": 60,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Several studies have assessed the role of vitamin D deficiency in the perinatal period (by utilization of biobanks and dried blood spot samples) upon risk for MS, with conflicting results. Swedish studies have looked at the relationship of 25-hydroxyvitamin D levels during gestation (25) and in the neonatal period (26) as it relates to risk of developing MS in these offspring.",
      "key": "5f9eaa53e7d3558d037089c657617ae6",
      "line": 128,
      "relation": "association",
      "source": 60,
      "target": 0
    },
    {
      "annotations": {
        "Anatomy": {
          "neonate stage": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Lower neonatal vitamin D levels were associated with a higher MS risk, with every 25 nmol/L increase in 25-hydroxyvitamin D conferring a 30% reduced risk for MS (27).",
      "key": "3e32fd147807c573d6b246ae91fd9975",
      "line": 137,
      "relation": "negativeCorrelation",
      "source": 60,
      "target": 7
    },
    {
      "annotations": {
        "Anatomy": {
          "serum": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "The seroprevalence rates of remote EBV infection are higher in MS as compared to healthy controls, in both adult (31) and pediatric MS patients; however, this association is more striking when studied in the pediatric MS population given the lower rate of seroprevalence in healthy children and adolescents (32,33).",
      "key": "98e73c8c4d310683a72439b0e510d933",
      "line": 147,
      "relation": "increases",
      "source": 60,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "A role for human herpesvirus 6 (HHV-6) has been suggested from studies demonstrating elevated antibodies against HHV-6 in serum of MS patients in addition to the detection of viral DNA within the plaques of MS patients (38).",
      "key": "e4af588736be18e1967af4715f9cc854",
      "line": 170,
      "relation": "association",
      "source": 60,
      "target": 66
    },
    {
      "annotations": {
        "Anatomy": {
          "serum": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Herpesviridae Infections": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "A role for human herpesvirus 6 (HHV-6) has been suggested from studies demonstrating elevated antibodies against HHV-6 in serum of MS patients in addition to the detection of viral DNA within the plaques of MS patients (38).",
      "key": "06fcc83de04942312c598cdba09faa41",
      "line": 173,
      "relation": "increases",
      "source": 60,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Deeper investigation revealed these to be part of an HLA haplotype – in particular, the HLA-DRB1*15:01 allele has consistently been shown to be an independent risk factor for MS, particularly in populations of European ancestry, with an odds ratio (OR) of approximately 3 (75).",
      "key": "4313d945c517f9ac26ba1019a9fce17e",
      "line": 259,
      "relation": "positiveCorrelation",
      "source": 60,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Given this, there has been exploration into the idea that genetic variants within the mitochondrial DNA (mtDNA) could play a role in MS risk. Mitochondrial haplogroups have been associated with adult-onset MS (82).",
      "key": "8a241084e5940042bff1fa6059bc7a90",
      "line": 271,
      "relation": "association",
      "source": 60,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Children with HLADRB1*15 alleles were more likely to ultimately meet diagnostic criteria for MS (OR=2.7). This effect was greater in children of European ancestry (OR=3.3). No difference in DRB1*15 allele frequency was found between children with monophasic acute demyelinating syndrome and unaffected controls (84), suggesting that the HLA-DRB1*15 allele is a risk factor for pediatric MS but not monophasic demyelinating events (23).",
      "key": "ba14b37108773e09efe7fd17d0b6cc95",
      "line": 282,
      "relation": "association",
      "source": 60,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "bc4b6dbd5d4cf412884c6fafe0e6d6be",
      "line": 411,
      "relation": "association",
      "source": 60,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "b5ddf3be90e0fa8115b8c090e4bad432",
      "line": 412,
      "relation": "association",
      "source": 60,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "e887626a1b858613e96e5fca128ff00b",
      "line": 413,
      "relation": "association",
      "source": 60,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "6e8bc50bebd7753cce0d7b18e588c1d1",
      "line": 414,
      "relation": "decreases",
      "source": 60,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "0ad885b8facef36477a540ac053ffa1b",
      "line": 415,
      "relation": "association",
      "source": 60,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Lifestyle and environmental factors are established contributors to risk for MS.",
      "key": "5b0c9dcbbb6102f5782fa8973d40b1a7",
      "line": 81,
      "relation": "association",
      "source": 78,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "There is a positive association between latitude and prevalence of MS at a global level, unexplained by the genetic distribution of high-risk alleles (12).",
      "key": "7e4047dcc7d5497ee221ea77f3c92e58",
      "line": 87,
      "relation": "positiveCorrelation",
      "source": 87,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Early work has shown that duration of exposure to sunlight and sunlight intensity are associated with MS risk",
      "key": "8784df362a6123b050195e247a358ae0",
      "line": 92,
      "relation": "association",
      "source": 85,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Furthermore, both outdoor work and residence in a high sunlight area have been associated with lower MS mortality rates (17).",
      "key": "b4e9ac09f55e8c4dd0b28e55fdc87893",
      "line": 99,
      "relation": "decreases",
      "source": 85,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Early work has shown that duration of exposure to sunlight and sunlight intensity are associated with MS risk",
      "key": "23d13ccf7f0218818ac2a5fd4615002d",
      "line": 93,
      "relation": "association",
      "source": 20,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Furthermore, both outdoor work and residence in a high sunlight area have been associated with lower MS mortality rates (17).",
      "key": "e34a6e9d608822895b512d61c0947d52",
      "line": 100,
      "relation": "decreases",
      "source": 86,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Encephalomyelitis, Autoimmune, Experimental": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Work in the experimental allergic encephalomyelitis (EAE) mouse model has shown beneficial effects of UVR exposure on EAE disease, independent of vitamin D status (20).",
      "key": "320920d1c05852051f82fab451d0fe52",
      "line": 108,
      "relation": "decreases",
      "source": 6,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "The results demonstrated a significant decrease in risk of MS associated with increasing 25-hydroxyvitamin D among whites.",
      "key": "a4e7497286a4a9089bcf09e2e45464ed",
      "line": 116,
      "relation": "decreases",
      "source": 0,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Several studies have assessed the role of vitamin D deficiency in the perinatal period (by utilization of biobanks and dried blood spot samples) upon risk for MS, with conflicting results. Swedish studies have looked at the relationship of 25-hydroxyvitamin D levels during gestation (25) and in the neonatal period (26) as it relates to risk of developing MS in these offspring.",
      "key": "789eca5e53204b40f487b85d7bf3d617",
      "line": 128,
      "relation": "association",
      "source": 0,
      "target": 60
    },
    {
      "annotations": {
        "Anatomy": {
          "neonate stage": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Lower neonatal vitamin D levels were associated with a higher MS risk, with every 25 nmol/L increase in 25-hydroxyvitamin D conferring a 30% reduced risk for MS (27).",
      "key": "a62cc4f3926310c51af668c0c48c1536",
      "line": 139,
      "relation": "decreases",
      "source": 0,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "In addition, low vitamin D levels have been implicated in risk for pediatric MS (23) and the prevalence and degree of low vitamin D are comparable between adult and pediatric MS patients (24).",
      "key": "7bb92af7a8e609c80137e0148b9ef649",
      "line": 122,
      "relation": "negativeCorrelation",
      "source": 7,
      "target": 88
    },
    {
      "annotations": {
        "Anatomy": {
          "neonate stage": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Lower neonatal vitamin D levels were associated with a higher MS risk, with every 25 nmol/L increase in 25-hydroxyvitamin D conferring a 30% reduced risk for MS (27).",
      "key": "77b392eb3814d412e6d0c46e89f8effb",
      "line": 137,
      "relation": "negativeCorrelation",
      "source": 7,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "MS disease-modifying therapies and vitamin D supplementation have a modulatory effect on the human gut microbial composition (62).",
      "key": "0923cc6c41c7556ae780222a7f787b0e",
      "line": 247,
      "relation": "regulates",
      "source": 7,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "In addition, low vitamin D levels have been implicated in risk for pediatric MS (23) and the prevalence and degree of low vitamin D are comparable between adult and pediatric MS patients (24).",
      "key": "389ba82f47aaa32412a57d0203fd7f92",
      "line": 122,
      "relation": "negativeCorrelation",
      "source": 88,
      "target": 7
    },
    {
      "annotations": {
        "Anatomy": {
          "serum": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "The seroprevalence rates of remote EBV infection are higher in MS as compared to healthy controls, in both adult (31) and pediatric MS patients; however, this association is more striking when studied in the pediatric MS population given the lower rate of seroprevalence in healthy children and adolescents (32,33).",
      "key": "44c476ef23669f80c68fda11cbdae0cd",
      "line": 148,
      "relation": "directlyIncreases",
      "source": 88,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Indeed, pediatric MS case-control studies have demonstrated differences in gut flora (at a taxa-level) between cohorts(61).",
      "key": "805eb1b4d0907b101b37a43032d65ba9",
      "line": 241,
      "relation": "regulates",
      "source": 88,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "In pediatric MS cohorts, HLA-DRB1 is associated with the EBNA-1 antibody response, suggesting that HLA risk genes have an important influence on the immune response to viral infection (99).",
      "key": "abb518758f7a0e18b482ee8d7ad83ee8",
      "line": 342,
      "relation": "increases",
      "source": 88,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "8670ab204bca3c69a762d5e6881ba91a",
      "line": 405,
      "relation": "association",
      "source": 88,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "0050472caaba905ce24f61a79d59ecdc",
      "line": 406,
      "relation": "association",
      "source": 88,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "6a5feffe337bdf02a61c47344f3db9d7",
      "line": 407,
      "relation": "association",
      "source": 88,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "5b0c78693b1ba4d20a856ba6993ee290",
      "line": 408,
      "relation": "decreases",
      "source": 88,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "9484c33bd154a8f623021331396d01a1",
      "line": 409,
      "relation": "association",
      "source": 88,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Epstein-Barr Virus Infections": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Evidence suggests that a pediatric MS patient’s antibody response to remote EBV is modified by the HLA-DRB1 allele (35)",
      "key": "505255e7cb21c94d9c9c61754878441b",
      "line": 156,
      "relation": "regulates",
      "source": 57,
      "target": 21
    },
    {
      "key": "f959fd7bdad7d0de4e6e941e2aba072e",
      "relation": "partOf",
      "source": 57,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Remote cytomegalovirus (CMV) infection, denoted by the presence of positive serologic anti-CMV IgG, appears to be protective against pediatric MS diagnosis (OR of 0.27; 95% CI 0.11-0.67) (36).",
      "key": "489bcddb84f88b999d3d54bfff49902a",
      "line": 162,
      "relation": "increases",
      "source": 63,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Remote cytomegalovirus (CMV) infection, denoted by the presence of positive serologic anti-CMV IgG, appears to be protective against pediatric MS diagnosis (OR of 0.27; 95% CI 0.11-0.67) (36).",
      "key": "58017509bc38a1dfc6390aa9a630f5db",
      "line": 163,
      "relation": "decreases",
      "source": 63,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Remote cytomegalovirus (CMV) infection, denoted by the presence of positive serologic anti-CMV IgG, appears to be protective against pediatric MS diagnosis (OR of 0.27; 95% CI 0.11-0.67) (36).",
      "key": "ccdee6bd49402842f95fb8b5ca543eec",
      "line": 164,
      "relation": "decreases",
      "source": 61,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "A role for human herpesvirus 6 (HHV-6) has been suggested from studies demonstrating elevated antibodies against HHV-6 in serum of MS patients in addition to the detection of viral DNA within the plaques of MS patients (38).",
      "key": "7f3bd16a0c4ac0151a7be26c09aef624",
      "line": 170,
      "relation": "association",
      "source": 66,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Smoking has been shown to increase risk of MS; furthermore, risk increases in a dose-dependent fashion with higher cumulative smoking dose.",
      "key": "ce9fe5085d8ed74c3ef50bbbc43db5d5",
      "line": 180,
      "relation": "increases",
      "source": 84,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Smoking has also been shown to increase the risk of MS disability progression (41).",
      "key": "af16961ce2ead2686b062d3f20fee5c8",
      "line": 198,
      "relation": "increases",
      "source": 84,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Despite this, oral tobacco use has not been associated with elevated risk for MS, which suggests that nicotine is not the responsible agent (39).",
      "key": "e914b29d18d3bca58b93be9992b7010d",
      "line": 185,
      "relation": "causesNoChange",
      "source": 5,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Despite this, oral tobacco use has not been associated with elevated risk for MS, which suggests that nicotine is not the responsible agent (39).",
      "key": "ab4c62c43b5cba8a6d1a6baa08a68647",
      "line": 186,
      "relation": "causesNoChange",
      "source": 1,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "The frequency of exposure to parental passive smoking was associated with an increased risk for MS (RR 2.12, 95% CI 1.43-3.15).",
      "key": "55b15e10cc6b453ac0b5eb7587f55233",
      "line": 192,
      "relation": "increases",
      "source": 4,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "2331ece1e67ce0b806bbde1573a91625",
      "line": 405,
      "relation": "association",
      "source": 64,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "a91edb71e60ef274df3e2a7d1220b703",
      "line": 411,
      "relation": "association",
      "source": 64,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Following this, it was demonstrated that childhood obesity is independently associated with an increased risk of pediatric MS and CIS in girls (but not boys).This risk appears to be dose dependent as well, with higher weight categories being associated with a higher risk (50).",
      "key": "55a2100cda9ffc6df1053d9ac5d447ea",
      "line": 208,
      "relation": "increases",
      "source": 77,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Following this, it was demonstrated that childhood obesity is independently associated with an increased risk of pediatric MS and CIS in girls (but not boys).This risk appears to be dose dependent as well, with higher weight categories being associated with a higher risk (50).",
      "key": "356b34e8855886183428d433d7729d91",
      "line": 213,
      "relation": "increases",
      "source": 70,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "A more recent study has demonstrated that a higher body mass index (BMI) in early adolescence is a risk factor for pediatric MS in post-pubertal girls (OR=1.60, 95% CI: 1.12-2.27) and boys (OR=1.43, 95% CI: 1.08-1.88) (51).",
      "key": "52a919ca947d58d23042eb8102a25002",
      "line": 218,
      "relation": "increases",
      "source": 69,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Encephalomyelitis, Autoimmune, Experimental": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Though human studies are confounded due to reliance on patient recollection and nonspecific survey-based questionnaires, high salt diet has been shown in EAE models to increase risk of autoimmune disease and drive severity of EAE due to induction of pathogenic TH17 cells (52).",
      "key": "293b0f70d049c7a50a0e4dd937c8eb32",
      "line": 225,
      "relation": "positiveCorrelation",
      "source": 22,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Though human studies are confounded due to reliance on patient recollection and nonspecific survey-based questionnaires, high salt diet has been shown in EAE models to increase risk of autoimmune disease and drive severity of EAE due to induction of pathogenic TH17 cells (52).",
      "key": "b6b3646f4ddd0015ba401fefb8593056",
      "line": 227,
      "relation": "decreases",
      "source": 22,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Though human studies are confounded due to reliance on patient recollection and nonspecific survey-based questionnaires, high salt diet has been shown in EAE models to increase risk of autoimmune disease and drive severity of EAE due to induction of pathogenic TH17 cells (52).",
      "key": "7526f6ed3ad307df0b3b05c8aeb5ee57",
      "line": 229,
      "relation": "decreases",
      "source": 22,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Encephalomyelitis, Autoimmune, Experimental": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Though human studies are confounded due to reliance on patient recollection and nonspecific survey-based questionnaires, high salt diet has been shown in EAE models to increase risk of autoimmune disease and drive severity of EAE due to induction of pathogenic TH17 cells (52).",
      "key": "2ed054c747669d6751ff2c69d9c86472",
      "line": 225,
      "relation": "positiveCorrelation",
      "source": 62,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Though human studies are confounded due to reliance on patient recollection and nonspecific survey-based questionnaires, high salt diet has been shown in EAE models to increase risk of autoimmune disease and drive severity of EAE due to induction of pathogenic TH17 cells (52).",
      "key": "59e88eae66d7338480334ba23a602ac9",
      "line": 228,
      "relation": "increases",
      "source": 54,
      "target": 65
    },
    {
      "key": "265cb5d352563e032d55512c9c876b48",
      "relation": "hasVariant",
      "source": 53,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "The bacterial milieu within the gastrointestinal tract has a substantial influence on an individual’s immune profile and response – including development of the immune system, protection against pathogens, and maintenance of immune response (57).",
      "key": "c6765161b446d17d29f0f2ee9e956b4c",
      "line": 234,
      "relation": "regulates",
      "source": 73,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "The bacterial milieu within the gastrointestinal tract has a substantial influence on an individual’s immune profile and response – including development of the immune system, protection against pathogens, and maintenance of immune response (57).",
      "key": "335bb40b199c10b321a4066413205dd4",
      "line": 235,
      "relation": "regulates",
      "source": 73,
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "The bacterial milieu within the gastrointestinal tract has a substantial influence on an individual’s immune profile and response – including development of the immune system, protection against pathogens, and maintenance of immune response (57).",
      "key": "5f0ec0860af156b5eba892084fa40373",
      "line": 236,
      "relation": "regulates",
      "source": 73,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "viral infectious disease": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "In pediatric MS cohorts, HLA-DRB1 is associated with the EBNA-1 antibody response, suggesting that HLA risk genes have an important influence on the immune response to viral infection (99).",
      "key": "ac4030426306ff4c4657af13e998eb2e",
      "line": 344,
      "relation": "association",
      "source": 19,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "To-date, taking into account the entire human genome, the MHC, located on chromosome 6, comprises the single largest genetic contribution to MS susceptibility. HLA genes encode for cell surface glycoproteins with a primary role in presenting antigenic peptide fragments to T-cells (74)",
      "key": "0a114b3c0f164965901a36273e83720c",
      "line": 252,
      "relation": "increases",
      "source": 47,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "viral infectious disease": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "In pediatric MS cohorts, HLA-DRB1 is associated with the EBNA-1 antibody response, suggesting that HLA risk genes have an important influence on the immune response to viral infection (99).",
      "key": "9764dcfb50d9a5da0bd701904bcbb426",
      "line": 344,
      "relation": "association",
      "source": 47,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "To-date, taking into account the entire human genome, the MHC, located on chromosome 6, comprises the single largest genetic contribution to MS susceptibility. HLA genes encode for cell surface glycoproteins with a primary role in presenting antigenic peptide fragments to T-cells (74)",
      "key": "ed7601dc86e16405201e7b53a6afdc8c",
      "line": 253,
      "relation": "increases",
      "source": 34,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "To-date, taking into account the entire human genome, the MHC, located on chromosome 6, comprises the single largest genetic contribution to MS susceptibility. HLA genes encode for cell surface glycoproteins with a primary role in presenting antigenic peptide fragments to T-cells (74)",
      "key": "2af4f3232bc025ec234f54947486ff86",
      "line": 254,
      "relation": "increases",
      "source": 52,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Deeper investigation revealed these to be part of an HLA haplotype – in particular, the HLA-DRB1*15:01 allele has consistently been shown to be an independent risk factor for MS, particularly in populations of European ancestry, with an odds ratio (OR) of approximately 3 (75).",
      "key": "250aeb882799dd569d9a8e6bf55949d6",
      "line": 259,
      "relation": "positiveCorrelation",
      "source": 35,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "the HLA-DRB1*15:03 allele is a risk factor in African Americans, while the HLA-A*02 allele appears to confer a protective effect against MS, with an OR of approximately 0.6 (79).",
      "key": "ec1fe6db865dc8dce4621ab5685a3c56",
      "line": 265,
      "relation": "increases",
      "source": 48,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "the HLA-DRB1*15:03 allele is a risk factor in African Americans, while the HLA-A*02 allele appears to confer a protective effect against MS, with an OR of approximately 0.6 (79).",
      "key": "f87569bbb0458efef4c15f87034a469b",
      "line": 266,
      "relation": "decreases",
      "source": 50,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Given this, there has been exploration into the idea that genetic variants within the mitochondrial DNA (mtDNA) could play a role in MS risk. Mitochondrial haplogroups have been associated with adult-onset MS (82).",
      "key": "cb3208d2bd656c517bf686cf0c772325",
      "line": 271,
      "relation": "association",
      "source": 2,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Many of the currently-identified haplogroups have SNPs that occur in genes that encode subunits of the oxidative phosphorylation complex - deficiencies of which can result in bioenergetic dysfunction.",
      "key": "fe3ad573097f2215de39fa3feaaea76a",
      "line": 276,
      "relation": "positiveCorrelation",
      "source": 23,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Many of the currently-identified haplogroups have SNPs that occur in genes that encode subunits of the oxidative phosphorylation complex - deficiencies of which can result in bioenergetic dysfunction.",
      "key": "b12d3054090419fd076356fc47015500",
      "line": 276,
      "relation": "positiveCorrelation",
      "source": 71,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Children with HLADRB1*15 alleles were more likely to ultimately meet diagnostic criteria for MS (OR=2.7). This effect was greater in children of European ancestry (OR=3.3). No difference in DRB1*15 allele frequency was found between children with monophasic acute demyelinating syndrome and unaffected controls (84), suggesting that the HLA-DRB1*15 allele is a risk factor for pediatric MS but not monophasic demyelinating events (23).",
      "key": "cef940263bb31d5999ff5ca5fc08d10d",
      "line": 282,
      "relation": "association",
      "source": 37,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Demyelinating Diseases": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Children with HLADRB1*15 alleles were more likely to ultimately meet diagnostic criteria for MS (OR=2.7). This effect was greater in children of European ancestry (OR=3.3). No difference in DRB1*15 allele frequency was found between children with monophasic acute demyelinating syndrome and unaffected controls (84), suggesting that the HLA-DRB1*15 allele is a risk factor for pediatric MS but not monophasic demyelinating events (23).",
      "key": "4f9953b3feaa511b8b0a519636fb8285",
      "line": 284,
      "relation": "causesNoChange",
      "source": 37,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Smoking": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Smoking greatly increases MS risk in individuals who are positive for the HLA-DRB1*15 allele and negative for the HLA-A*02 allele (OR 13.5) compared to nonsmokers with the same HLA genotype (OR 4.9) (101)",
      "key": "2f917cc88fbba3a49d13b8a05585ef4c",
      "line": 357,
      "relation": "increases",
      "source": 37,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Obesity": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Obesity has been linked to HLA risk alleles, as obese (BMI≥27) individuals, who were positive for HLADRB1* 15 and negative for HLA-A*02 exhibited an increased risk of MS (OR 16.2) compared to those with BMI < 27 with the same HLA genotype risk factors (OR 5.1) (103).",
      "key": "85deb240c235deee857edf51bc700612",
      "line": 367,
      "relation": "increases",
      "source": 37,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Children with HLADRB1*15 alleles were more likely to ultimately meet diagnostic criteria for MS (OR=2.7). This effect was greater in children of European ancestry (OR=3.3). No difference in DRB1*15 allele frequency was found between children with monophasic acute demyelinating syndrome and unaffected controls (84), suggesting that the HLA-DRB1*15 allele is a risk factor for pediatric MS but not monophasic demyelinating events (23).",
      "key": "582ac79adbbf4692425ff35c9dd35803",
      "line": 286,
      "relation": "increases",
      "source": 37,
      "target": 88
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Studies have identified tissue-specific (e.g. within the CNS white matter of MS patients) upregulation of the peptidylargininedeiminase-2 (PAD2) enzyme by way of DNA hypomethylation.",
      "key": "b1d73df583407751c3646e285cecbeec",
      "line": 294,
      "relation": "increases",
      "source": 16,
      "target": 44
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "This upregulation of PAD2 leads to production of a less-stable form of myelin basic protein and subsequent loss of immune tolerance (89).",
      "key": "0d9ee5a96c8870ce48af4064f79cc88e",
      "line": 300,
      "relation": "increases",
      "source": 44,
      "target": 43
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "This upregulation of PAD2 leads to production of a less-stable form of myelin basic protein and subsequent loss of immune tolerance (89).",
      "key": "57b79e8d66d23bf7f93b66d4dcc145b7",
      "line": 302,
      "relation": "decreases",
      "source": 44,
      "target": 75
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "This upregulation of PAD2 leads to production of a less-stable form of myelin basic protein and subsequent loss of immune tolerance (89).",
      "key": "986a52c8cb0b47b0c0b1b306346f2a03",
      "line": 301,
      "relation": "decreases",
      "source": 43,
      "target": 75
    },
    {
      "key": "11f51c60af4473fd7329311aad127373",
      "relation": "hasVariant",
      "source": 42,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "e98e14e8771ef8098c99c0c60627321e",
      "line": 311,
      "relation": "increases",
      "source": 28,
      "target": 39
    },
    {
      "key": "59275a8aa77812fbb33698ae224a9eb3",
      "relation": "hasVariant",
      "source": 27,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "ac813273cac88dc9e48d5a0a46deae90",
      "line": 316,
      "relation": "regulates",
      "source": 39,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "b32c3f84542c50bd35521d1972c13df6",
      "line": 321,
      "relation": "regulates",
      "source": 39,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "c961530d7af49c25f74e5406cce84597",
      "line": 312,
      "relation": "increases",
      "source": 26,
      "target": 38
    },
    {
      "key": "b4fa8e47345e4db77e4b989bf504de6a",
      "relation": "hasVariant",
      "source": 25,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "bd8ee1790432e3203c4e6e573d2c3d99",
      "line": 317,
      "relation": "regulates",
      "source": 38,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "4837cc6870265248f24bc6d1ae6b580a",
      "line": 322,
      "relation": "regulates",
      "source": 38,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "eb397779aed2bcba8863e1d1c4acdbd8",
      "line": 313,
      "relation": "increases",
      "source": 30,
      "target": 40
    },
    {
      "key": "3f939ca731ab693a97dd86029003f23a",
      "relation": "hasVariant",
      "source": 29,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "727cc1d8312c557952d61b304e90e01c",
      "line": 318,
      "relation": "regulates",
      "source": 40,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "46b2dccd72fd88a16a5ebbf9783c55f7",
      "line": 323,
      "relation": "regulates",
      "source": 40,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "c25920d6dde81b9926a977dea2b7958a",
      "line": 314,
      "relation": "increases",
      "source": 32,
      "target": 41
    },
    {
      "key": "69b33d992c9c8f89aaea1695c3e2758b",
      "relation": "hasVariant",
      "source": 31,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "19676cb330afcf36494f0b57ae3ba130",
      "line": 319,
      "relation": "regulates",
      "source": 41,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation –including IFNG, FOXP3, IL-13 and IL-17 (91) – ultimately resulting in increased expression of these genes.",
      "key": "67a8ece89d50788a34dde06867174fcc",
      "line": 324,
      "relation": "regulates",
      "source": 41,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Other studies have demonstrated evidence of hypermethylation in genes involved with immune system regulation (e.g. SHP-1), resulting in reduced genetic expression and a resultant increase in leukocyte-mediated inflammation (92).",
      "key": "6f49d7a3a87319895e53e5fa28859b1e",
      "line": 331,
      "relation": "regulates",
      "source": 33,
      "target": 3
    },
    {
      "annotations": {
        "Cell": {
          "leukocyte": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Other studies have demonstrated evidence of hypermethylation in genes involved with immune system regulation (e.g. SHP-1), resulting in reduced genetic expression and a resultant increase in leukocyte-mediated inflammation (92).",
      "key": "632d643a4f775ac01723be47c9f2dd63",
      "line": 334,
      "relation": "decreases",
      "source": 33,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Other studies have demonstrated evidence of hypermethylation in genes involved with immune system regulation (e.g. SHP-1), resulting in reduced genetic expression and a resultant increase in leukocyte-mediated inflammation (92).",
      "key": "2b0939daf61863ecb0e6a0d561f3e589",
      "line": 332,
      "relation": "decreases",
      "source": 46,
      "target": 33
    },
    {
      "annotations": {
        "Cell": {
          "leukocyte": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Other studies have demonstrated evidence of hypermethylation in genes involved with immune system regulation (e.g. SHP-1), resulting in reduced genetic expression and a resultant increase in leukocyte-mediated inflammation (92).",
      "key": "df47f52d33587b8d819c94fbb561fefb",
      "line": 335,
      "relation": "increases",
      "source": 46,
      "target": 82
    },
    {
      "key": "aa6e07213f3565be868fbcd7353b1108",
      "relation": "hasVariant",
      "source": 45,
      "target": 46
    },
    {
      "key": "87c0f7ebff8f7b6a37935158e9e8bf7a",
      "relation": "partOf",
      "source": 36,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "It also appears that viral infections may help to shape the early immune response, as early life herpes simplex virus-1 (HSV-1) infection appears to be protective in those who are HLA-DRB1*15 positive (100).",
      "key": "a1addd7b143ab212080b981f5a5b29ff",
      "line": 350,
      "relation": "decreases",
      "source": 51,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Smoking": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Smoking greatly increases MS risk in individuals who are positive for the HLA-DRB1*15 allele and negative for the HLA-A*02 allele (OR 13.5) compared to nonsmokers with the same HLA genotype (OR 4.9) (101)",
      "key": "291d75f7575611742a02013b1175ff08",
      "line": 358,
      "relation": "increases",
      "source": 56,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Obesity": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Obesity has been linked to HLA risk alleles, as obese (BMI≥27) individuals, who were positive for HLADRB1* 15 and negative for HLA-A*02 exhibited an increased risk of MS (OR 16.2) compared to those with BMI < 27 with the same HLA genotype risk factors (OR 5.1) (103).",
      "key": "749758b533a384959d452644b8cde095",
      "line": 368,
      "relation": "increases",
      "source": 56,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "c0701391b9c58904ca5fa9c0dbcb6a51",
      "line": 374,
      "relation": "decreases",
      "source": 8,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "7cd0e6bf0d20d58361b85e7ba642857d",
      "line": 378,
      "relation": "decreases",
      "source": 8,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "de42f5d7efcbd0250e2f8626c3bce9bb",
      "line": 382,
      "relation": "isA",
      "source": 8,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "aed2813da26f1081dacb00d1a5875536",
      "line": 375,
      "relation": "decreases",
      "source": 14,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "7154690ac2f557ed74e13d579e806313",
      "line": 379,
      "relation": "decreases",
      "source": 14,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "6496d62d396a0a68b5d82e483017740c",
      "line": 383,
      "relation": "isA",
      "source": 14,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "64c87d2e1cd22c56a696bcedfa32a0be",
      "line": 376,
      "relation": "decreases",
      "source": 15,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "f7cedd17cf3c0e2ab2e9947155e40c3e",
      "line": 380,
      "relation": "decreases",
      "source": 15,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration.",
      "key": "3bb8ea51f0ebe112c1837fb93bae98a0",
      "line": 384,
      "relation": "isA",
      "source": 15,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "b3f3382125df27d51b8c6d99d02efcc7",
      "line": 389,
      "relation": "decreases",
      "source": 9,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "cc78c0fc6df8f08a203f1b9636b3c2c9",
      "line": 395,
      "relation": "isA",
      "source": 9,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "fcde4e319e44ea78ac0800056b5cf48a",
      "line": 390,
      "relation": "decreases",
      "source": 11,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "9a5269692c1c5616156223d62ee7728e",
      "line": 396,
      "relation": "isA",
      "source": 11,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "3270b5c633a10070a02783b2debce6cb",
      "line": 391,
      "relation": "decreases",
      "source": 12,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "5e8b70a3cbda80770d51a47612925beb",
      "line": 397,
      "relation": "isA",
      "source": 12,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "8d4548dee933873d3c6a78ef02b13064",
      "line": 392,
      "relation": "decreases",
      "source": 10,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "f68f73aee8d7611fff8d97f36da1e1ed",
      "line": 398,
      "relation": "isA",
      "source": 10,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "9e40b7425eb33b1cc2a59b3754f64c10",
      "line": 393,
      "relation": "decreases",
      "source": 13,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS.",
      "key": "cbb45e8c952fbf6e69ec2a38e8078652",
      "line": 399,
      "relation": "isA",
      "source": 13,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "068bd7a1ff5900bffb18ace38594e675",
      "line": 406,
      "relation": "association",
      "source": 59,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "e7aaf307fa6db5c0842b3719674f743f",
      "line": 412,
      "relation": "association",
      "source": 59,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "31ff2a5f047cc295730a5c47acb09ad0",
      "line": 407,
      "relation": "association",
      "source": 80,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "eeec115f0da07c95e609919ff2a5e5e6",
      "line": 413,
      "relation": "association",
      "source": 80,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "fc67750fa494871b1a7dfe6ca7dc16db",
      "line": 409,
      "relation": "association",
      "source": 58,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Brenton JN",
          "Cappa R",
          "Theroux L"
        ],
        "date": "2017-10-01",
        "db": "PubMed",
        "db_id": "28843454",
        "db_name": "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.",
        "first": "Cappa R",
        "journal": "Pediatric neurology",
        "last": "Brenton JN",
        "pages": "17-28",
        "volume": "75"
      },
      "evidence": "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent.",
      "key": "b529247d053b4a3d1d6d96011de12dc5",
      "line": 415,
      "relation": "association",
      "source": 58,
      "target": 60
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"24,25-Dihydroxyvitamin D\")",
      "concept": {
        "name": "24,25-Dihydroxyvitamin D",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "020789bfaa7f2c6833d6d35efe5ff7f8"
    },
    {
      "bel": "a(CHEBI:nicotine)",
      "concept": {
        "name": "nicotine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "44ed555f78bacda2933ddef1d4280ce9"
    },
    {
      "bel": "a(MESH:\"DNA, Mitochondrial\")",
      "concept": {
        "name": "DNA, Mitochondrial",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "448ef9c24f89f09d23d3ad285d9bfa70"
    },
    {
      "bel": "a(MESH:\"Immune System\")",
      "concept": {
        "name": "Immune System",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "4aaf98db101d0e929bfb5c7510fd17dd"
    },
    {
      "bel": "a(MESH:\"Tobacco Smoke Pollution\")",
      "concept": {
        "name": "Tobacco Smoke Pollution",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "8e9e99ded33f72871d7267f38365972c"
    },
    {
      "bel": "a(MESH:\"Tobacco, Smokeless\")",
      "concept": {
        "name": "Tobacco, Smokeless",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "11d378b468e881cd115118b255e9afca"
    },
    {
      "bel": "a(MESH:\"Ultraviolet Rays\")",
      "concept": {
        "name": "Ultraviolet Rays",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "e78a4d06e644ca93c82e0f1dd8fadade"
    },
    {
      "bel": "a(MESH:\"Vitamin D\")",
      "concept": {
        "name": "Vitamin D",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "3568d3e3b0c75b4f1fd3534788b8c5a2"
    },
    {
      "bel": "a(PUBCHEM:107970)",
      "concept": {
        "name": "107970",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "69a2f60643b06d7fecc8ceef6a18ff0b"
    },
    {
      "bel": "a(PUBCHEM:135314782)",
      "concept": {
        "name": "135314782",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "e6cb2faf400c0ee34f5d8166513bf9de"
    },
    {
      "bel": "a(PUBCHEM:135330159)",
      "concept": {
        "name": "135330159",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "80c053cf1e3d707cb3713755a96479cd"
    },
    {
      "bel": "a(PUBCHEM:135341754)",
      "concept": {
        "name": "135341754",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "3e47c46a116dab364aec058281c72dac"
    },
    {
      "bel": "a(PUBCHEM:2907)",
      "concept": {
        "name": "2907",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "52f7c5c56d47a00c733901d012738847"
    },
    {
      "bel": "a(PUBCHEM:46504469)",
      "concept": {
        "name": "46504469",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "5277371ca87cc9e79db0cdcf8dad9517"
    },
    {
      "bel": "a(PUBCHEM:54684141)",
      "concept": {
        "name": "54684141",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "07b337c03ab28dbef0530a6469a93aeb"
    },
    {
      "bel": "a(PUBCHEM:637568)",
      "concept": {
        "name": "637568",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "cfb6e2041ec338daa24a91a45673cf19"
    },
    {
      "bel": "bp(GO:\"DNA hypomethylation\")",
      "concept": {
        "name": "DNA hypomethylation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "149b6f8d06cdfbd209ebddc96b0e5c40"
    },
    {
      "bel": "bp(GO:\"T cell antigen processing and presentation\")",
      "concept": {
        "name": "T cell antigen processing and presentation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "2f04ca16055d4048ed816b71146cffcd"
    },
    {
      "bel": "bp(GO:\"T cell differentiation\")",
      "concept": {
        "name": "T cell differentiation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d8ba3b5db5422435fab5439f4a806991"
    },
    {
      "bel": "bp(GO:\"immune response\")",
      "concept": {
        "name": "immune response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "a7608eff244d93cdc19d37fbc1489683"
    },
    {
      "bel": "bp(GO:\"response to light intensity\")",
      "concept": {
        "name": "response to light intensity",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "41f2981b12e84f697b2610421167f9b2"
    },
    {
      "bel": "bp(MESH:\"Antibody Formation\")",
      "concept": {
        "name": "Antibody Formation",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "084e453b3506a56910068e5bf9ac4f97"
    },
    {
      "bel": "bp(MESH:\"Diet, Sodium-Restricted\")",
      "concept": {
        "name": "Diet, Sodium-Restricted",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "c431b1bd6bc4011ad531960ee17a5121"
    },
    {
      "bel": "bp(MESH:\"Oxidative Phosphorylation\")",
      "concept": {
        "name": "Oxidative Phosphorylation",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "6a2d7c3da19d0f482dbc70e56ee7da26"
    },
    {
      "bel": "composite(p(EFO:\"Anti-Epstein-Barr virus early antigen IgG measurement\"), p(NCIT:C52341))",
      "function": "Composite",
      "id": "71f3196418d48d1034392ae972caff06",
      "members": [
        {
          "bel": "p(EFO:\"Anti-Epstein-Barr virus early antigen IgG measurement\")",
          "concept": {
            "name": "Anti-Epstein-Barr virus early antigen IgG measurement",
            "namespace": "EFO"
          },
          "function": "Protein",
          "id": "c4383fba631acf5e5099d0a67479fe5f"
        },
        {
          "bel": "p(NCIT:C52341)",
          "concept": {
            "name": "C52341",
            "namespace": "NCIT"
          },
          "function": "Protein",
          "id": "96d293bb877c2890a65920c6489a026a"
        }
      ]
    },
    {
      "bel": "g(HGNC:FOXP3)",
      "concept": {
        "name": "FOXP3",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "834c0ea657adc8b6aa08bb14b718804f"
    },
    {
      "bel": "g(HGNC:FOXP3, var(\"NCIT:C121521\"))",
      "concept": {
        "name": "FOXP3",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "93b8af98216307b61931c23832a016cd",
      "variants": [
        {
          "hgvs": "NCIT:C121521",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "g(HGNC:IFNG)",
      "concept": {
        "name": "IFNG",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "2ae2c632d8bc0921fbbc3e09fcc45e96"
    },
    {
      "bel": "g(HGNC:IFNG, var(\"NCIT:C121521\"))",
      "concept": {
        "name": "IFNG",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "b700366c668a2c6bfeb2eec7b15816ff",
      "variants": [
        {
          "hgvs": "NCIT:C121521",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "g(HGNC:IL13)",
      "concept": {
        "name": "IL13",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "0b09f615c5de88c56c0d095f1c39b3b4"
    },
    {
      "bel": "g(HGNC:IL13, var(\"NCIT:C121521\"))",
      "concept": {
        "name": "IL13",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "a15f649b4efa7235e9f235aac4ae4ed8",
      "variants": [
        {
          "hgvs": "NCIT:C121521",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "g(HGNC:IL17A)",
      "concept": {
        "name": "IL17A",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "9ce0824adb81001f5044cbadb373812c"
    },
    {
      "bel": "g(HGNC:IL17A, var(\"NCIT:C121521\"))",
      "concept": {
        "name": "IL17A",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "2ae43f53dace418b8e2c65df1a3acf02",
      "variants": [
        {
          "hgvs": "NCIT:C121521",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "g(HGNC:PTPN6)",
      "concept": {
        "name": "PTPN6",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "dc5221a1de50f920dde0578c5af1c444"
    },
    {
      "bel": "g(HGNCGENEFAMILY:\"Histocompatibility complex\")",
      "concept": {
        "name": "Histocompatibility complex",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Gene",
      "id": "3c4f99aaeb95a1930d5b709b73c499c8"
    },
    {
      "bel": "g(IMGTHLA:HLA00865)",
      "concept": {
        "name": "HLA00865",
        "namespace": "IMGTHLA"
      },
      "function": "Gene",
      "id": "a26647a6e661178edc0803ed992034ce"
    },
    {
      "bel": "p(EFO:\"Anti-Epstein-Barr virus early antigen IgG measurement\")",
      "concept": {
        "name": "Anti-Epstein-Barr virus early antigen IgG measurement",
        "namespace": "EFO"
      },
      "function": "Protein",
      "id": "c4383fba631acf5e5099d0a67479fe5f"
    },
    {
      "bel": "p(HGNC:\"HLA-DRB1\")",
      "concept": {
        "name": "HLA-DRB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "046dd1ead21fe1ececa6f91663d08a7c"
    },
    {
      "bel": "p(HGNC:FOXP3)",
      "concept": {
        "name": "FOXP3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c7d84ece4399b8a2d71b1963911d1875"
    },
    {
      "bel": "p(HGNC:IFNG)",
      "concept": {
        "name": "IFNG",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "20367a6ea54ae1032be4f48276f3c524"
    },
    {
      "bel": "p(HGNC:IL13)",
      "concept": {
        "name": "IL13",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "148a1f49575f988c19d1ea5763eedfd0"
    },
    {
      "bel": "p(HGNC:IL17A)",
      "concept": {
        "name": "IL17A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7565adaa388ec2dccc2d062833d6f622"
    },
    {
      "bel": "p(HGNC:MBP)",
      "concept": {
        "name": "MBP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "648e8365c587b532946d8a49fc81cb90"
    },
    {
      "bel": "p(HGNC:MBP, var(\"?\"))",
      "concept": {
        "name": "MBP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "21e97cb04acce632eb43fe07f5dbaad3",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:PADI2)",
      "concept": {
        "name": "PADI2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "59de93ea39a2951ef63ea3dce125861e"
    },
    {
      "bel": "p(HGNC:PTPN6)",
      "concept": {
        "name": "PTPN6",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "825220799075c7b129d1902cdf11020d"
    },
    {
      "bel": "p(HGNC:PTPN6, pmod(NCIT:C20102))",
      "concept": {
        "name": "PTPN6",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "baecf2d2cfff84830afd599da6c4a637",
      "variants": [
        {
          "concept": {
            "name": "C20102",
            "namespace": "NCIT"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Histocompatibility complex\")",
      "concept": {
        "name": "Histocompatibility complex",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "3d152370eff0617f44e6b9a446bc410b"
    },
    {
      "bel": "p(IMGTHLA:HLA00870)",
      "concept": {
        "name": "HLA00870",
        "namespace": "IMGTHLA"
      },
      "function": "Protein",
      "id": "d0c3d42a09f3238f9836bf24f0587302"
    },
    {
      "bel": "p(MESH:\"Antibodies, Monoclonal\")",
      "concept": {
        "name": "Antibodies, Monoclonal",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "981f47ac703582b8464d68d85dbaaa4d"
    },
    {
      "bel": "p(MESH:\"HLA Antigens\")",
      "concept": {
        "name": "HLA Antigens",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "79a1b8c0418382ec6a82bee526f9c199"
    },
    {
      "bel": "p(MESH:\"Herpesvirus 1, Human\")",
      "concept": {
        "name": "Herpesvirus 1, Human",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "1778537af7d6a02c3ec78a87b58f28ad"
    },
    {
      "bel": "p(MESH:\"Membrane Glycoproteins\")",
      "concept": {
        "name": "Membrane Glycoproteins",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "848d49f4d29a44ec2e12b96093774df5"
    },
    {
      "bel": "p(MESH:\"Th17 Cells\")",
      "concept": {
        "name": "Th17 Cells",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "8a6255cbe2fbe791c08e05fcfc3ac728"
    },
    {
      "bel": "p(MESH:\"Th17 Cells\", var(\"?\"))",
      "concept": {
        "name": "Th17 Cells",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "954b0d4185cce3c3e540a8e50357b6e4",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(MESH:Antibodies)",
      "concept": {
        "name": "Antibodies",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "0c889f1acd1690024513d943546b9397"
    },
    {
      "bel": "p(NCIT:C150640)",
      "concept": {
        "name": "C150640",
        "namespace": "NCIT"
      },
      "function": "Protein",
      "id": "db5b9a5110ec509fd161bc1057721bad"
    },
    {
      "bel": "p(NCIT:C52341)",
      "concept": {
        "name": "C52341",
        "namespace": "NCIT"
      },
      "function": "Protein",
      "id": "96d293bb877c2890a65920c6489a026a"
    },
    {
      "bel": "path(DOID:\"cognitive disorder\")",
      "concept": {
        "name": "cognitive disorder",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "3660255d04a8aebceee02e591d5f43b6"
    },
    {
      "bel": "path(DOID:\"mental depression\")",
      "concept": {
        "name": "mental depression",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "444223db67421fa96923920d0a8fd533"
    },
    {
      "bel": "path(DOID:\"multiple sclerosis\")",
      "concept": {
        "name": "multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "828e65d53fe5c29b364f79cfd5304f90"
    },
    {
      "bel": "path(EFO:\"Anti-cytomegalovirus IgG measurement\")",
      "concept": {
        "name": "Anti-cytomegalovirus IgG measurement",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "0059e24fcce16b1c74e12450c2fde1b7"
    },
    {
      "bel": "path(EFO:\"autoimmune disease\")",
      "concept": {
        "name": "autoimmune disease",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "6ade60b38188c8a6fbfaa2a06fa3a6a2"
    },
    {
      "bel": "path(EFO:\"cytomegalovirus infection\")",
      "concept": {
        "name": "cytomegalovirus infection",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "793332763135525586c36dafa0c4c556"
    },
    {
      "bel": "path(EFO:\"developmental disability\")",
      "concept": {
        "name": "developmental disability",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "3bdbbef6469debc760b4ca2ff0b70159"
    },
    {
      "bel": "path(EFO:\"experimental autoimmune encephalomyelitis\")",
      "concept": {
        "name": "experimental autoimmune encephalomyelitis",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "32b1c17fbec51b6b7c44e27150d888c7"
    },
    {
      "bel": "path(EFO:\"human herpesvirus 6 seropositivity\")",
      "concept": {
        "name": "human herpesvirus 6 seropositivity",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "03ed4c77bf2486b17942ebd92ef0e2e6"
    },
    {
      "bel": "path(EFO:\"relapsing-remitting multiple sclerosis\")",
      "concept": {
        "name": "relapsing-remitting multiple sclerosis",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "0b63326bd6673eef7d38a067cb765089"
    },
    {
      "bel": "path(MESH:\"Administration, Oral\")",
      "concept": {
        "name": "Administration, Oral",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "dceb88cbb2c665aee613f0bf702ff669"
    },
    {
      "bel": "path(MESH:\"Body Mass Index\")",
      "concept": {
        "name": "Body Mass Index",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ef220ea8596adf1e6d288893518466e2"
    },
    {
      "bel": "path(MESH:\"Body Weight\")",
      "concept": {
        "name": "Body Weight",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4b8c7b8db7dcd7679c99d903e387a9f6"
    },
    {
      "bel": "path(MESH:\"Energy Metabolism\")",
      "concept": {
        "name": "Energy Metabolism",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "266b2ade166522498effb10b3b6890c9"
    },
    {
      "bel": "path(MESH:\"Epstein-Barr Virus Infections\")",
      "concept": {
        "name": "Epstein-Barr Virus Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "152f451c5e17ac13db8d9a8224992412"
    },
    {
      "bel": "path(MESH:\"Gastrointestinal Microbiome\")",
      "concept": {
        "name": "Gastrointestinal Microbiome",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "23ac8135b8a71c31ee00fc9de8afd1cb"
    },
    {
      "bel": "path(MESH:\"Home Infusion Therapy\")",
      "concept": {
        "name": "Home Infusion Therapy",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2ca0fd422af4763861c5c38e4f332749"
    },
    {
      "bel": "path(MESH:\"Immune Tolerance\")",
      "concept": {
        "name": "Immune Tolerance",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "1d6a108b246fd15eac3a275f5e7e79bf"
    },
    {
      "bel": "path(MESH:\"Life Style\")",
      "concept": {
        "name": "Life Style",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "cf6b9cde10ef447cb5d12fc6f02ef5cb"
    },
    {
      "bel": "path(MESH:\"Pediatric Obesity\")",
      "concept": {
        "name": "Pediatric Obesity",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0c921fcd3c1639123844897f2d8b86e6"
    },
    {
      "bel": "path(MESH:Environment)",
      "concept": {
        "name": "Environment",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "a15e4a1dbdd737f6405e7c3e8cdf6bbe"
    },
    {
      "bel": "path(MESH:Exercise)",
      "concept": {
        "name": "Exercise",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "de6191d5a04d16c06b916d59485b25a5"
    },
    {
      "bel": "path(MESH:Fatigue)",
      "concept": {
        "name": "Fatigue",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "d9f7d216d60384a034383bbc94db85cd"
    },
    {
      "bel": "path(MESH:Immunity)",
      "concept": {
        "name": "Immunity",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "424748a9a78045ed955401a3dcedc709"
    },
    {
      "bel": "path(MESH:Inflammation)",
      "concept": {
        "name": "Inflammation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10cd96fd4056a5e6c27264e0130e89f9"
    },
    {
      "bel": "path(MESH:Mortality)",
      "concept": {
        "name": "Mortality",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "df8c4e5f3d406d3ef8f732f01595a9a6"
    },
    {
      "bel": "path(MESH:Smoking)",
      "concept": {
        "name": "Smoking",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "421977e25516b65692cc5c7ed794a7eb"
    },
    {
      "bel": "path(MESH:Sunlight)",
      "concept": {
        "name": "Sunlight",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "144ab081ad5f866a9e3416ecc36f755c"
    },
    {
      "bel": "path(MESH:Work)",
      "concept": {
        "name": "Work",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "af4a383c0e554094dc34cf0922ce6f8b"
    },
    {
      "bel": "path(NCIT:C68642)",
      "concept": {
        "name": "C68642",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "b36a864c22375faace65cde706be8808"
    },
    {
      "bel": "path(ORPHANET:477738)",
      "concept": {
        "name": "477738",
        "namespace": "ORPHANET"
      },
      "function": "Pathology",
      "id": "9e225f3ae848a13edc483d75ea0c9236"
    }
  ]
}